1. Home
  2. ACOG vs VTVT Comparison

ACOG vs VTVT Comparison

Compare ACOG & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.81

Market Cap

129.4M

Sector

N/A

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$35.95

Market Cap

143.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
VTVT
Founded
2000
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.4M
143.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
ACOG
VTVT
Price
$5.81
$35.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$18.00
$53.00
AVG Volume (30 Days)
57.2K
45.6K
Earning Date
03-26-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$132.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.75
$14.00
52 Week High
$10.88
$44.00

Technical Indicators

Market Signals
Indicator
ACOG
VTVT
Relative Strength Index (RSI) 51.49 50.25
Support Level $5.16 $31.42
Resistance Level $6.67 $42.71
Average True Range (ATR) 0.34 3.86
MACD -0.02 0.01
Stochastic Oscillator 51.00 57.94

Price Performance

Historical Comparison
ACOG
VTVT

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.

Share on Social Networks: